Retatrutide vs Amycretin: Why This Comparison Isn't Fair Yet

Introduction

Every number favors retatrutide in this comparison. More weight loss. Better HbA1c reduction. More patients studied. If you stopped reading after the data table below, you'd walk away thinking retatrutide has simply won.

That conclusion would be premature, and explaining why is the actual point of this article. Amycretin — recently given the official name zenagamtide by its developer, Novo Nordisk — has only completed Phase 2 trials. Retatrutide has completed multiple Phase 3 trials. Comparing a Phase 3 drug's confirmed numbers against a Phase 2 drug's early numbers isn't really comparing efficacy — it's comparing how far along each drug is in proving itself. Here's the data, and here's why the gap between these two drugs is more about timing than biology.

Two Different Mechanisms

Retatrutide is a triple agonist: GLP-1 suppresses appetite and slows digestion, GIP improves insulin sensitivity, and glucagon increases energy expenditure and fat oxidation — three distinct pathways working together.

Zenagamtide (amycretin) combines just two: GLP-1 and amylin receptor activation, built into a single molecule. Amylin is a hormone co-secreted with insulin that contributes to satiety and slows gastric emptying — a pathway that's biologically distinct from GIP or glucagon. This targets the same general biology as Novo Nordisk's CagriSema (semaglutide + cagrilintide, an amylin analog), but where CagriSema combines two separate molecules, zenagamtide is engineered as one molecule that activates both receptors itself.

Neither approach is inherently superior. They're different bets on which hormonal combination produces the best outcome — and right now, only one of those bets has been tested at Phase 3 scale.

The Data: Phase 3 vs Phase 2

Note: these are cross-phase comparisons — retatrutide's figures come from completed Phase 3 trials, zenagamtide's from Phase 2. This table reflects "best available data for each drug today," not a final efficacy verdict.

The pattern in the table is consistent: retatrutide leads on every measure. But both drugs showed no weight loss plateau at their respective trial endpoints — meaning neither has shown its ceiling yet. Zenagamtide's Phase 2 T2D trial ran 36 weeks; retatrutide's comparable trial ran 40 weeks, and its obesity trials ran 68–80 weeks. Longer exposure has historically meant more weight loss for drugs in this class, so part of retatrutide's lead may simply reflect that its trials ran longer, not that the drug is more potent dose-for-dose.

What We Know About Zenagamtide's Phase 2 Trials

The Type 2 Diabetes Trial

NCT06542874 was a 36-week, randomized, placebo-controlled, dose-finding study in 262 adults with type 2 diabetes (baseline HbA1c 7.0–10.0%) on stable metformin, with or without an SGLT2 inhibitor. Presented at the 2026 ADA Scientific Sessions, results showed weight loss up to 14.5–14.6%, HbA1c reduction up to 1.7 percentage points, and roughly 89% of participants reaching HbA1c below 7%. Safety was described as consistent with other incretin and amylin-based therapies.

The Obesity Trial

An earlier, separate Phase 2 trial in a non-diabetic obesity population reported weight loss up to 22% over 36 weeks — the result that led Novo Nordisk to advance zenagamtide into Phase 3 obesity development, which began enrolling in early 2026.

What's Next

Phase 3 for the diabetes indication is planned to start in the second half of 2026. Based on typical trial durations in this drug class (36+ weeks, plus enrollment and analysis time), a reasonable estimate puts the first Phase 3 diabetes readout sometime in 2027 — though Novo Nordisk hasn't published a specific date, so this is an informed projection rather than a confirmed timeline.

Administration: A Potential Edge for Amycretin

Zenagamtide is being developed for both once-weekly subcutaneous injection and once-daily oral administration. If the oral version succeeds in Phase 3, that would be a real convenience advantage — retatrutide currently has no oral formulation in development (that distinction belongs to Eli Lilly's separate orforglipron/Foundayo program).

Worth noting: in Phase 2 testing, the oral version of zenagamtide showed lower placebo-adjusted weight loss than the injectable version — a pattern common across oral peptide drugs in this class, where bioavailability is harder to optimize than with an injection. Whether that gap narrows in Phase 3 is one of the open questions for this drug.

Why the Phase 2 vs Phase 3 Gap Actually Matters

Phase 2 results are not a reliable predictor of final Phase 3 outcomes. Some drugs maintain their Phase 2 signal into Phase 3; others see it shift as trial populations grow larger and more representative of real-world patients — sometimes upward, sometimes downward. Until zenagamtide's Phase 3 obesity and diabetes programs report, any head-to-head comparison with retatrutide's already-confirmed Phase 3 numbers should be read as "where things stand today," not a final verdict on which mechanism wins.

For where retatrutide currently stands across its own Phase 3 program, see our complete retatrutide guide.

Conclusion

Retatrutide and zenagamtide (amycretin) represent genuinely different mechanistic bets — triple GLP-1/GIP/glucagon agonism versus dual GLP-1/amylin agonism — and on every number available today, retatrutide leads: 28.3–28.7% weight loss in obesity versus up to 22%, and 16.8% with -2.0% HbA1c in diabetes versus up to 14.6% with -1.7%. But that lead is partly an artifact of where each drug sits in development, not a settled mechanism comparison. Retatrutide's numbers are Phase 3-confirmed across multiple trials; zenagamtide's are early Phase 2 signals from shorter trials.

The fairer comparison arrives once zenagamtide's Phase 3 programs report — likely 2027 or later for the diabetes indication. Until then, this is a comparison between a drug that has proven itself and one that's still in the process of trying to.

Sources

• Novo Nordisk. "Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes." Presented at ADA Scientific Sessions, June 5, 2026.
• Mora P, Aroda V, Asong M, et al. "Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: phase 2b results in T2D." Poster presentation, American Diabetes Association Scientific Sessions, June 2026.
• Novo Nordisk. "Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes." November 25, 2025.
• Bajaj HS, et al. "Efficacy and safety of retatrutide... (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.